Date: 2012-07-10
Type of information: Fundraising
Company: Hemarina (France)
Investors: Inserm Transfert Initiative (France)
Finistère Angels (France)
Armor Angels (France)
XMP (France)
Arkéa Capital Investissement (France)
a family office represented and mandated by Maurice Lesaffre
Amount: €6.3 million
Funding type: series B financing round
Planned used: This investment will help Hemarina to bring its first product to the market, in the field of organ transplant, and to strengthen its organization and infrastructure, sustain its R&D programs, and finalize strategic alliances under discussion.
Others: Hemarina, a biotechnology start-up developing innovative solutions for patients and healthcare industry based on its universal oxygen carriers products, has raised €6.3 million in a Series B financing round. The syndicate was led by Inserm Transfert Initiative and includes historical investors such as Finistère Angels, Armor Angels, XMP and Arkéa Capital Investissement and also a new entrant which is a family office represented and mandated by M. Maurice Lesaffre.
Hemarina develops extracellular hemoglobin with a broad range of medical and industrial applications. The company has four core business programs: organs transplantation and tissues conservation; blood oxygen carriers; infections and wound healing; and bioproduction. The Morlaix based company is predicting to bring its first medical application product by end of 2013 in the field of kidney transplant.
Therapeutic area: Transplantation - Technology - Services
